摘要
Endoglin (CD105) is a type-1 integral transmembrane glycoprotein and coreceptor for transforming growth factor-β (TGF-β) ligands. The endoglin/TGF-β signaling pathway regulates hemostasis, cell proliferation/migration, extracellular matrix (ECM) synthesis and angiogenesis. Angiogenesis contributes to early progression, invasion, postoperative recurrence, and metastasis in hepatocellular carcinoma (HCC), one of the most widespread malignancies globally. Endoglin is overexpressed in newly formed HCC microvessels. It increases microvessel density in cirrhotic and regenerative HCC nodules. In addition, circulating endoglin is present in HCC patients, suggesting potential for use as a diagnostic or prognostic factor. HCC angiogenesis is dynamic and endoglin expression varies by stage. TRC105 (carotuximab) is an antibody against endoglin, and three of its clinical trials were related to liver diseases. A partial response was achieved when combining TRC105 with sorafenib. Although antiangiogenic therapy still carries some risks, combination therapy with endoglin inhibitors or other targeted therapies holds promise.
| 原文 | 英語 |
|---|---|
| 文章編號 | 3208 |
| 頁（從 - 到） | 1-12 |
| 頁數 | 12 |
| 期刊 | International Journal of Molecular Sciences |
| 卷 | 22 |
| 發行號 | 6 |
| DOIs | |
| 出版狀態 | 已出版 - 02 03 2021 |
文獻附註
Publisher Copyright:© 2021 by the authors. Licensee MDPI, Basel, Switzerland.